Education
About Us
Working with TipRanks
Follow Us
Alector Inc (ALEC)
NASDAQ:ALEC
ALEC Stock Chart & Stats
$1.61
-$0.09(-4.55%)
At close: 4:00 PM EST
$1.61
-$0.09(-4.55%)
Day’s Range― - ―
52-Week Range$0.87 - $6.14
Previous CloseN/A
Volume194.31K
Average Volume (3M)1.39M
Market Cap
$324.89M
Enterprise Value-$127.28M
Total Cash (Recent Filing)$307.28M
Total Debt (Recent Filing)$39.48M
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Nov 11, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding101,212,326
10 Day Avg. Volume1,531,125
30 Day Avg. Volume1,386,763
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.39
Enterprise Value/Revenue-1.57
Enterprise Value/Gross Profit-4.05
Enterprise Value/Ebitda0.99
Forecast
1Y Price Target
$2.20Price Target Upside36.65% Upside
Rating ConsensusHold
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Business DevelopmentThere is increasing interest in blood-brain barrier crossing technology for neuro-focused indications, suggesting the possibility of business development activity that could result in non-dilutive funding.
Pipeline DiversificationA diversified pipeline spanning Alzheimer’s, Parkinson’s, and siRNA programs positions Alector as more than a single asset story, giving investors asymmetric upside across multiple scenario outcomes.
Regulatory StrategyAlector offers a near-term binary catalyst with the pivotal INFRONT-3 readout in FTD-GRN, where strong biomarker and MRI signals de-risk the program and create multiple regulatory paths, including accelerated approval.
Bears Say
Clinical Trial OutcomesThe Phase III INFRONT-3 study evaluating latozinemab (AL001) in frontotemporal dementia due to a progranulin gene mutation did not meet its co-primary endpoint of slowing FTD-GRN progression.
Financial StrainA significant workforce reduction by 49% is seen as a necessary step but highlights financial strain.
Uncertainty In PGRN ValueThe failure of latozinemab in INFRONT-3 highlights that biomarker modulation alone is insufficient without downstream clinical impact.
Alector News
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $0.87 and its highest was $6.14 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is $324.89M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Nov 11, 2025 which is in 18 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on Aug 07, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.461 by $0.161.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.41.
How many shares outstanding does Alector Inc have?
Alector Inc has 101,212,326 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.461. Following the earnings report the stock price went up 47.26%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in ALEC
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.20 (36.65% Upside)
$2.20 (36.65% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 9.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $241.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-65.74%
12-Months-Change
Fundamentals
Return on Equity
-103.98%
Trailing 12-Months
Asset Growth
-37.55%
Trailing 12-Months
Company Description
Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented several positive developments, including strong financial health, upcoming trial data, and completion of enrollment for a key program. However, significant challenges remain, such as regulatory hurdles and the complexity of diagnosing and treating FTD. The balance of promising advancements and existing challenges suggests a cautiously optimistic outlook.View all ALEC earnings summariesALEC Stock 12 Month Forecast
Average Price Target
$2.20
▲(36.65% Upside)
Technical Analysis
AC Immune SA
―
I-MAB
―
Foghorn Therapeutics
―
Vor Biopharma
―
Neumora Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---